First-Line Pembrolizumab Monotherapy for Advanced NSCLC With Programmed Death-Ligand 1 Expression Greater Than or Equal to 50%: Real-World Study Including Older Patients in Japan.
JTO Clin Res Rep
; 3(9): 100397, 2022 Sep.
Article
in En
| MEDLINE
| ID: mdl-36065450
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Type of study:
Prognostic_studies
Language:
En
Journal:
JTO Clin Res Rep
Year:
2022
Document type:
Article
Affiliation country:
Japan